<?xml version="1.0" encoding="UTF-8"?>
<GaPExchange xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:noNamespaceSchemaLocation="./dbGaPEx2.1.5.xsd">

<MetaVariables>
	<Submitter/>
	<Method/>
</MetaVariables>
<MetaLinks/>

<Projects>
	<Project/>
</Projects>

<Studies>

<Study source="dbGaP" accession="phs000224.v2.p1" parentStudy="phs000224.v2.p1" createDate="2015-02-27" modDate="2015-04-01">

<Configuration>
	<Data_Provider><![CDATA[
		<table border="1">
		<tr><th>Title</th><th>Name</th><th>Institute</th></tr>
		<tr><td>Principal Investigator</td><td>Richard A. Spritz, MD</td><td>University of Colorado Denver, Aurora, CO, USA</td></tr>
		<tr><td>Funding Source</td><td>R01AR056292</td><td>National Institutes of Health, Bethesda, MD, USA</td></tr>
		</table>
	]]></Data_Provider>
	<StudyNameEntrez>VitGene Generalized Vitiligo Genetics Study</StudyNameEntrez>
	<StudyNameReportPage>VitGene Generalized Vitiligo Genetics Study-Phase 2</StudyNameReportPage>
	<StudyTypes>
		<StudyType>Case-Control</StudyType>
		<StudyType>Cohort</StudyType>
	</StudyTypes>
	<Description><![CDATA[
<p>Generalized vitiligo is an autoimmune disease in which melanocyte loss results in patchy depigmentation of skin and hair. For this second GWAS of generalized vitiligo, SNPs were genotyped in 400 generalized vitiligo cases of European-derived white (EUR) ancestry using the Illumina 660K array. The data were combined with those of Phase 1 to provide 80% power to OR 1.3.</p>]]>
	</Description>
	<StudyInEx><![CDATA[
<p>Cases:<br/> Inclusion: EUR; must meet strict clinical diagnostic criteria for generalized vitiligo<br/> Exclusion: Non-EUR, must not have any form of congenital hypopigmentation, segmental vitiligo, any questionable diagnosis<br/> </p>]]>
	</StudyInEx>
	<StudyProjects>
		<Project/>
	</StudyProjects>
	<Publications>
		<Publication>
			<Pubmed pmid="20410501"/>
		</Publication>
		<Publication>
			<Pubmed pmid="20526340"/>
		</Publication>
		<Publication>
			<Pubmed pmid="21085187"/>
		</Publication>
		<Publication>
			<Pubmed pmid="21326295"/>
		</Publication>
		<Publication>
			<Pubmed pmid="22561518"/>
		</Publication>
		<Publication>
			<Pubmed pmid="25479423"/>
		</Publication>
	</Publications>
	<Diseases>
		<Disease vocab_source="MESH" vocab_term="Vitiligo"/>
	</Diseases>
	<Attributions>
		<Header title="Principal Investigator">
			<AttName>Richard A. Spritz, MD</AttName>
			<Institution>University of Colorado Denver, Aurora, CO, USA</Institution>
		</Header>
		<Header title="Funding Source">
			<AttName>R01AR056292</AttName>
			<Institution>National Institutes of Health, Bethesda, MD, USA</Institution>
		</Header>
	</Attributions>
	<DisplayPublicSummary>yes</DisplayPublicSummary>
	<ConsentGroups>
		<ConsentGroup groupNum="1" shortName="DS-VTO" longName="Disease-Specific (Vitiligo)"/>
		<ConsentGroup groupNum="2" shortName="DS-VAD" longName="Disease-Specific (Vitiligo or Autoimmune Disorders)"/>
	</ConsentGroups>
</Configuration>

  <AuthorizedAccess>
    <DacInfo ssDacId="0">
      <DacName>NIAMS</DacName>
      <DacFullName>NIAMS</DacFullName>
      <DacEmail>0</DacEmail>
      <DacPhone></DacPhone>
      <DacUrl></DacUrl>
    </DacInfo>
    <Policy Policy_ID="phs000224.v2.p1_policy" ref_ssDacId="0">
      <DisplayResearchStatement>yes</DisplayResearchStatement>
      <DisplayPublicSummary>yes</DisplayPublicSummary>
      <EmbargoLength>0</EmbargoLength>
      <YearsUntilRenewal>1</YearsUntilRenewal>
      <WeeksCancelRequest>8</WeeksCancelRequest>
      <PdfSupplementReqired>no</PdfSupplementReqired>
      <AcknowledgementText>
        <para>
          http://dbgap.ncbi.nlm.nih.gov/aa/wga.cgi?page=DUC&amp;view_pdf&amp;stacc=phs000224.v2.p1
        </para>
      </AcknowledgementText>
      <DocumentSet>
        <DataUseCertificate Label="Data Use Certificate" FilePath="https://dbgap.ncbi.nlm.nih.gov/aa/wga.cgi?page=DUC&amp;view_pdf&amp;stacc=phs000224.v2.p1" FileName=""/>
      </DocumentSet>
    </Policy>
    <ConsentGroups>
      <ParticipantSet groupNum-REF="1">
        <ConsentName>Disease-Specific (Vitiligo)</ConsentName>
        <ConsentAbbrev>DS-VTO</ConsentAbbrev>
        <UseLimitation>Use of the data must be related to Vitiligo.</UseLimitation>
        <IrbRequired>No</IrbRequired>
      </ParticipantSet>
      <ParticipantSet groupNum-REF="2">
        <ConsentName>Disease-Specific (Vitiligo or Autoimmune Disorders)</ConsentName>
        <ConsentAbbrev>DS-VAD</ConsentAbbrev>
        <UseLimitation>Use of the data must be related to Vitiligo or Autoimmune Disorders.</UseLimitation>
        <IrbRequired>No</IrbRequired>
      </ParticipantSet>
    </ConsentGroups>
  </AuthorizedAccess>


</Study>

</Studies>

</GaPExchange>
